Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients
Expert Rev Neurother. 2023 Jul-Dec;23(11):945-953. doi: 10.1080/14737175.2023.2265068. Epub 2023 Oct 27.ABSTRACTINTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with symptoms that may persist in up to 90% of adults diagnosed during childhood and continue to cause significant impairment throughout the lifespan. In the United States (US), amphetamine and methylphenidate formulations have been available to treat ADHD for several decades. Only one nonstimulant, atomoxetine, was available for the treatment of ADHD in adults until recently. In April 2022, a second nonstimulant, v...
Source: Expert Review of Neurotherapeutics - October 17, 2023 Category: Neurology Authors: Ann Childress Robert Sottile Sherine Khanbijian Source Type: research
